Charles River Laboratories International, Inc. $CRL Shares Bought by Northwestern Mutual Wealth Management Co.

Northwestern Mutual Wealth Management Co. boosted its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 6,710.3% during the 4th quarter, Holdings Channel.com reports. The firm owned 74,641 shares of the medical research company’s stock after purchasing an additional 73,545 shares during the quarter. Northwestern Mutual Wealth Management Co.’s holdings in Charles River Laboratories International were worth $14,889,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Tema Etfs LLC acquired a new stake in Charles River Laboratories International during the 4th quarter worth about $26,000. Rothschild Investment LLC grew its position in Charles River Laboratories International by 82.4% during the 3rd quarter. Rothschild Investment LLC now owns 186 shares of the medical research company’s stock worth $29,000 after purchasing an additional 84 shares during the period. Atlantic Union Bankshares Corp purchased a new stake in shares of Charles River Laboratories International during the 3rd quarter worth about $31,000. Activest Wealth Management boosted its stake in shares of Charles River Laboratories International by 10,900.0% during the 4th quarter. Activest Wealth Management now owns 220 shares of the medical research company’s stock worth $44,000 after acquiring an additional 218 shares in the last quarter. Finally, Geneos Wealth Management Inc. boosted its stake in shares of Charles River Laboratories International by 98.0% during the 2nd quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock worth $44,000 after acquiring an additional 145 shares in the last quarter. 98.91% of the stock is owned by institutional investors and hedge funds.

Charles River Laboratories International Trading Up 2.5%

Shares of Charles River Laboratories International stock opened at $156.22 on Thursday. The company has a current ratio of 1.36, a quick ratio of 1.03 and a debt-to-equity ratio of 0.90. Charles River Laboratories International, Inc. has a twelve month low of $132.58 and a twelve month high of $228.88. The firm has a market capitalization of $7.53 billion, a PE ratio of -41.55, a P/E/G ratio of 1.74 and a beta of 1.44. The firm’s 50-day moving average price is $167.94 and its 200 day moving average price is $181.63.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Thursday, May 7th. The medical research company reported $2.06 EPS for the quarter, topping the consensus estimate of $1.96 by $0.10. Charles River Laboratories International had a positive return on equity of 15.36% and a negative net margin of 4.59%.The firm had revenue of $995.83 million during the quarter, compared to analysts’ expectations of $977.46 million. During the same period in the previous year, the business earned $2.34 earnings per share. The firm’s revenue for the quarter was up 1.2% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. On average, sell-side analysts predict that Charles River Laboratories International, Inc. will post 11.05 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on CRL shares. Robert W. Baird set a $213.00 target price on shares of Charles River Laboratories International in a research note on Friday, May 8th. Mizuho set a $192.00 target price on shares of Charles River Laboratories International in a research note on Friday, May 8th. Royal Bank Of Canada started coverage on shares of Charles River Laboratories International in a research note on Tuesday, April 14th. They set an “outperform” rating and a $215.00 target price on the stock. JPMorgan Chase & Co. lowered their target price on shares of Charles River Laboratories International from $165.00 to $160.00 and set a “neutral” rating on the stock in a research note on Monday, April 13th. Finally, Evercore reissued an “outperform” rating and set a $220.00 target price on shares of Charles River Laboratories International in a research note on Friday, May 8th. Eleven analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Charles River Laboratories International has an average rating of “Moderate Buy” and an average target price of $205.86.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.